Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 528, Issue 1-3, Pages 37-42Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2005.10.027
Keywords
Cdc25B; HTS (high throughput screening); selectivity; MCF-7; antiproliferation; Cdk1 (cell-cycle-dependent kinase 1)
Categories
Ask authors/readers for more resources
Cdc25B is a dual specific phosphatase, which plays a pivotal role in the activation of cell-cycle-dependent kinase 1 (Cdk1). A novel Cdc25B inhibitor, EK-6136, was identified by high throughput screening (HTS) using compounds from Korea Chemical Bank and examined for its biological effects. EK-6136 inhibited Cdc25B with an IC50 of 6.4 +/- 1.5 mu M. EK-6136 showed selectivity against several phosphatases including PTP-1B, CD45, Cdc25A, PP1, VHR and Yop. fit the inhibition kinetic study, EK-6136 displayed a mixed inhibition pattern with a K-i value of 7.8 +/- 1.2 mu M. Consistent with in vitro results, EK-6136 inhibited the proliferation of MCF-7 (human breast carcinoma), HT-29 (human colorectal adenocarcinoma) and A549 (lung carcinoma) cells with increased Cdk-1 phosphorylation. Herein, we propose that EK-6136 is an active HTS hit as a Cdc25B inhibitor with antiproliferative activity, and can be used for the design of more potent and selective antiproliferative agents. (c) 2005 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available